Integrating MajesTEC-9 Data Into Treatment Decisions for Relapsed/Refractory Multiple Myeloma

Building on the first patient case, Dr. Binod Dhakal and Dr. Prerna Mewawalla discuss how recently presented MajesTEC-9 data may influence treatment selection for patients with relapsed/refractory multiple myeloma (RRMM) who experience an early relapse following frontline therapy.

Dr. Mewawalla explains how remission duration, disease biology, patient age, and anti-CD38 treatment history factor into her interpretation of the available evidence and subsequent treatment recommendations.

While acknowledging the promising outcomes observed with BCMA-directed bispecific antibodies, she notes that a relatively early relapse following transplant may indicate more aggressive disease biology and supports consideration of CAR T-cell therapy for eligible patients.

The discussion also explores how anti-CD38 exposure versus true anti-CD38 refractoriness may influence the selection of combination versus monotherapy approaches.

Ultimately, the segment highlights the importance of integrating emerging clinical trial data with patient-specific factors and shared decision-making when developing individualized treatment strategies for RRMM.